Rxrx stock forecast.

Next reporting date: February 14, 2024: EPS forecast (this quarter) $0.95: Annual revenue (last year) $2.2B: Annual profit (last year) $42.8M: Net profit marginSee the latest Recursion Pharmaceuticals Inc Class A stock price (RXRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Recursion Pharmaceuticals (RXRX 7.88%) and Exact Sciences (EXAS 4.73%), two of Wood's larger biopharma holdings across her family of tech-oriented ETFs, are prime examples of the pros and cons ...View the latest Recursion Pharmaceuticals Inc. (RXRX) stock price, news, historical charts, analyst ratings and financial information from WSJ.As of Monday, July 24, Recursion Pharmaceuticals Inc’s RXRX share price has dipped by 7.69%, which has investors questioning if this is right time to buy. Premium ... Whether you decide it’s a good time to buy or sell Recursion Pharmaceuticals Inc’s stock based on its stock price forecast is ultimately up to you.

The company, currently valued at $1.60B, closed the last trade at $7.39 per share which meant it gained $0.54 on the day or 7.88% during that session. The RXRX stock price is -126.66% off its 52-week high price of $16.75 and 38.57% above the 52-week low of $4.54. If we look at the company’s 10-day average daily trading volume, we find that it ...Recursion Pharmaceuticals Stock Prediction. BSX. 63Jul 1 2021 Recursion Pharmaceuticals (RXRX) said Thursday it has signed a lease agreement with Vestar for an additional 100,000 square feet of space to double the size of its Salt Lake City headquarters. In 2018, the biotech firm signed a lease for 100,000 square feet of space at The Gateway complex in downtown Salt Lake City.

Zillow is worth $8.3 billion right now, so if it reaches its 2025 sales estimate and continues to grow thereafter, it should breeze past a $10 billion valuation by 2030. 2. Duolingo: Potential ...

Recursion has put together an intriguing pipeline with some intriguing targets, although none yet for its biggest partners. Read my analysis of RXRX stock here.People use statistics daily for weather forecasts, predicting disease, preparing for emergencies, medical research, political campaigns, tracking sales, genetics, insurance, the stock market and quality testing.2 days ago · RXRX has an Altman Z-Score of 1.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Recursion Pharmaceuticals, Inc. (RXRX) stock, including valuation metrics, financial numbers, share information and more. Find the latest Royalty Pharma plc (RPRX) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W - 6W ...

Find the latest RxSight, Inc. (RXST) stock quote, history, news and other vital information to help you with your stock trading and investing.

NVDA stock has risen 3% in July, outperforming the Nasdaq Index, and has surged 200% this year, ... RXRX). The biotech company’s stock surged over 120% following the announcement, ...

All 39 ARKG ETF Holdings. The portfolio of Cathie Wood updated daily. These are the positions, trades, and weight of all companies in her ARKG Genomic Revolution ETF. Search tickers or categories... Trader's Guide 2024 Ships December 21st.5 analysts have issued 12 month price objectives for Amneal Pharmaceuticals' stock. Their AMRX share price targets range from $3.00 to $7.00. On average, they anticipate the company's share price to reach $4.80 in the next year. This suggests a possible upside of 9.3% from the stock's current price.The Recursion Pharmaceuticals, Inc. stock price gained 7.88% on the last trading day (Friday, 1st Dec 2023), rising from $6.85 to $7.39. During the last trading day …3 апр. 2023 г. ... Unity Stock New CEO Prioritizes Investors Over Stock Price. Jose Najarro ... RXRX Stock Recursion Pharmaceuticals top stocks to buy in August.Insiders have purchased a total of 581,017 RXRX shares in the last 24 months for a total of $4,440,853.30 bought. Which Recursion Pharmaceuticals insiders have been selling company stock? The following insiders have sold RXRX shares in the last 24 months: Blake Borgeson ($2,846,394.44), Christopher Gibson ($14,439,192.59), …NVIDIA Corporation Common Stock. $416.10 +5.93 +1.45%. ARM. Arm Holdings plc American Depositary Shares. $51.32 -0.84 -1.61%. Find the latest analyst research for Recursion Pharmaceuticals, Inc ...Get the latest stock price for Recursion Pharmaceuticals Inc. (RXRX:US), plus the latest news, recent trades, charting, insider activity, ...

Research Recursion Pharmaceuticals' (Nasdaq:RXRX) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past …See the latest Recursion Pharmaceuticals Inc Class A stock price (RXRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Nov 7, 2023 · Analyst projections state that RXRX is forecast to be at a low of $9.00 and a high of $35.00. In order for the stock price to hit the forecast high, the stock would need to plunge -532.91% from its current level, while the stock would need to crash -62.75% from its current level to reach the projected low. 2013. 550. Chris Gibson. https://www.recursion.com. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which ..."Over the next 10 years, AI could increase productivity by 1.5% per year. And that could increase S&P500 profits by 30% or more over the next decade," Goldman Sach's senior strategist Ben Snider ...

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.33 per share a year ago.

Shares of RXRX rallied more than 75% on Wednesday, July 12. At one point, the stock traded as high as $14.99, up 121% on the day. Now trading above that level — and up in five of the last six ...Andrew Hopkins. https://www.exscientia.ai. Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient ...The U.S. National Weather Service (NWS) is a part of the National Oceanic and Atmospheric Administration (NOAA). Many people rely on the National Weather Service’s forecasts in order to better anticipate what the weather will be like so the...What is Recursion Pharmaceuticals, Inc. (RXRX) stock EPS forecast? Recursion Pharmaceuticals, Inc. missed analysts’ expectations during the last earnings period by 13.16% . Recursion Pharmaceuticals, Inc. reported earnings of -$ 0.43 per share on Nov 9, 2023, while the forecasted EPS was -$ 0.38.Nov 29, 2023 · Should You Buy or Sell Recursion Pharmaceuticals Stock? Get The Latest RXRX Stock Analysis, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat. Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s ...

Recursion Pharmaceuticals, Inc. (RXRX) : Free Stock Analysis Report. Omega Therapeutics, Inc. (OMGA) : Free Stock Analysis Report ... according to the …

He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis ...

A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Explore RXRX - Recursion Pharmaceuticals Inc Stock Price Forecast: Accurate short-term and long-term price predictions up to 2050. ... Stock Calculator; Dow: 35,088. ...Recursion Pharmaceuticals (RXRX 7.88%) and Exact Sciences (EXAS 4.73%), two of Wood's larger biopharma holdings across her family of tech-oriented ETFs, are prime examples of the pros and cons ...Next reporting date: February 14, 2024: EPS forecast (this quarter) $0.95: Annual revenue (last year) $2.2B: Annual profit (last year) $42.8M: Net profit marginFind the latest ARK Genomic Revolution ETF (ARKG) stock quote, history, news and other vital information to help you with your stock trading and investing.Before the stock market opened, RXRX stock had catapulted more than 130%. Nvidia stock rose 3.5% to 439.02. Recursion has a searchable data set spanning biology and chemistry. The company says its ...A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Nov 22, 2023 · The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target for the stock is $15.57, which implies that it could rise by about 120% over the next 12 months. The average price target for Recursion Pharmaceuticals is $16.60. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst …Both companies could tap into huge growth from the AI revolution in a few years. Schrödinger ( SDGR 2.90%) and Recursion Pharmaceuticals ( RXRX 4.40%) are both biotechs that want to use AI to ...In the last three months, insiders have sold 333,493 shares of company stock worth $2,375,196. 19.96% of the stock is currently owned by insiders. Wall Street Analysts Forecast GrowthAnalyst Forecast According to 6 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price forecast is $15.33, which is an increase of 107.44% from the latest price.

13 июл. 2023 г. ... #price and rxrx stock #chart. Furthermore it explains you the rxrx stock #forecast and how to do rxrx stock prediction. It will also help ...Meta Platforms ( META ): META’s revenues climbed 23% to $34.15 billion in its most recent quarter. Teradyne ( TER ): Resilient Teradyne outshone in the third quarter with an 80-cent Non-GAAP EPS ...Jul 1 2021 Recursion Pharmaceuticals (RXRX) said Thursday it has signed a lease agreement with Vestar for an additional 100,000 square feet of space to double the size of its Salt Lake City headquarters. In 2018, the biotech firm signed a lease for 100,000 square feet of space at The Gateway complex in downtown Salt Lake City. Instagram:https://instagram. cedearbuy tesla stockbest stock market apimeta stock price prediction 2023 2 days ago · RXRX has an Altman Z-Score of 1.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Recursion Pharmaceuticals, Inc. (RXRX) stock, including valuation metrics, financial numbers, share information and more. The exchange reported a loss of $2.43 per share, compared to forecasts of a $2.52 loss per share, according to the FactSet consensus. Revenue plummeted 75% to $629.1 million, but still beat ... bond bond auctionblue cross blue shield weight watchers The US$14.13 analyst price target for RXRX is 3.5% ... we will estimate the stock's intrinsic value by taking the forecast future cash flows of the company and discounting them back to today's ...RXRX Stock Rips on Nvidia Investment. Shares of RXRX rallied more than 75% on Wednesday, July 12. At one point, the stock traded as high as $14.99, up 121% on the day. t rowe price global technology fund Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been making great progress lately in being able to advance its pipeline. That's because it has been advancing two clinical candidates in phase 2 ...One thing we could say about the analysts on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - they aren't optimistic, having just made a major negative revision to their near-term (statutory ...Sep 22, 2023 · According to data from CNN Money, the company had 7 analysts offering 12-month price forecasts. The median target price was $14.00, with a high estimate of $35.00 and a low estimate of $9.00. The consensus among the 7 polled investment analysts was to hold the stock of Recursion Pharmaceuticals Inc. This rating had remained steady since ...